Adimab LLC. Announces Expansion Of Its Collaboration With GlaxoSmithKline For The Discovery Of Bispecific Antibodies
LEBANON, N.H.--(BUSINESS WIRE)--Adimab, LLC, a technology leader in the discovery of fully human antibodies and bispecifics, today announced that GlaxoSmithKline (GSK) has broadened its relationship with Adimab. Under an expanded collaboration, Adimab will build a unique custom library for GSK for use in generating bispecific antibody leads. Adimab will use that library as well as existing Adimab technology in collaboration with GSK to discover antibodies against multiple targets and generate bispecific antibodies against combinations of those targets. Adimab will also transfer the novel library to GSK for its internal use in the discovery of bispecifics. GSK will have the right to develop and commercialize therapeutic bispecifics generated from the library. Today’s announcement expands on Adimab’s first platform technology transfer and license agreement, which was entered into with GSK in 2013.
“GSK has an interest in rapidly assessing biology from bispecific molecules with various target combinations, and the Adimab platform fully provides us with the quality and speed we need”
“We are excited that GSK has decided to be the first company to take advantage of Adimab’s unique ability to generate focused antibody libraries for our partners,” said Tillman Gerngross, CEO and co-founder of Adimab. “The Adimab platform can identify highly specialized functional IgGs, and incorporate them rapidly into stable, well-expressing bispecific leads. Further, the Adimab platform is a protein engineering tool that allows us to optimize molecules in virtually any bispecific format.”
“GSK has an interest in rapidly assessing biology from bispecific molecules with various target combinations, and the Adimab platform fully provides us with the quality and speed we need,” said Neil Brewis, Head of Biopharmaceutical Research at GSK. “Our existing collaboration has been highly productive, and this expansion reflects our appreciation of Adimab’s capabilities and collaborative approach.”
Over the past five years, Adimab has established funded discovery collaborations with more than 25 companies. Adimab’s funded discovery partners include many leading pharmaceutical companies, such as Merck, Roche, Novartis, Eli Lilly, Genentech, Gilead, Kyowa Hakko Kirin and Celgene. Adimab has strategically partnered with many other companies as well, including Merrimack, Five Prime, Jounce, Innovent, Alector and Arsanis. In addition, Adimab has transferred its platform for broad use to GSK, Biogen Idec and Novo Nordisk.
Adimab's integrated antibody discovery and optimization platform provides unprecedented speed from antigen to purified, full-length human lgGs. Adimab offers fundamental advantages by delivering diverse panels of therapeutically relevant antibodies and bispecifics that meet the most aggressive standards for affinity, epitope coverage, species cross-reactivity and developability. Adimab enables its partners to rapidly expand their biologics pipelines through a broad array of technology access arrangements. For more information, visit www.adimab.com.